AOPs

OECD View API
Toggle for API info
The API endpoint defaults to 25 results per page, but you can adjust this by changing the per_page parameter in the URL.
Searches both title and fulltext content
Takes you to the requested AOP
Clear Search Terms Clears search terms and filters

Showing 501 to 525 of 558 AOPs

Clear Table Filters
ID Title Point of Contact License MIE AO OECD Status OECD Project
511 The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects Yanhong Wei BY-SA 1115: Increase, Reactive oxygen species 2161: Increase, Vascular disrupting effects
538 Adverse outcome pathway of PFAS-induced vascular disrupting effects via activating oxidative stress related pathways Yanhong Wei BY-SA None 2161: Increase, Vascular disrupting effects
117 Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) Charles Wood Open for adoption 25: Agonism, Androgen receptor 719: Increase, hepatocellular adenomas and carcinomas Under Development 1.26
164 Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse Charles Wood BY-SA 1038: Activation, beta-2 adrenergic receptor 1044: Promotion, mesovarian leiomyomas
163 PPARgamma activation leading to sarcomas in rats, mice, and hamsters Charles Wood BY-SA 1028: Activation of specific nuclear receptors, PPAR-gamma activation None
162 Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse Charles Wood BY-SA None 741: Increase, Adenomas/carcinomas (follicular cell)
121 Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) Charles Wood BY-SA 793: Increase, Urinary bladder calculi 797: Increase, Adenomas/carcinomas (urothelial)
120 Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) Charles Wood BY-SA 1617: Inhibition, 5α-reductase 745: Increase, Leydig cell tumors
119 Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) Charles Wood BY-SA 279: Thyroperoxidase, Inhibition 741: Increase, Adenomas/carcinomas (follicular cell)
118 Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) Charles Wood BY-SA 786: Increase, Cytotoxicity (hepatocytes) 719: Increase, hepatocellular adenomas and carcinomas
116 Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) Charles Wood BY-SA 783: Increase, Cytotoxicity (tubular epithelial cells) 713: Increase, Adenomas/carcinomas (renal tubular)
115 Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) Charles Wood BY-SA 780: Increase, Cytotoxicity (epithelial cells) 779: Increase, Papillomas/carcinomas (squamous cells)
114 HPPD inhibition leading to corneal papillomas and carcinomas (in rat) Charles Wood BY-SA 766: Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme 779: Increase, Papillomas/carcinomas (squamous cells)
105 Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) Charles Wood BY-SA 714: Increased, Binding of chemicals to 2u (serum) 713: Increase, Adenomas/carcinomas (renal tubular)
108 Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) Charles Wood BY-SA 724: Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme 719: Increase, hepatocellular adenomas and carcinomas
109 Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) Charles Wood BY-SA 770: Increase, Cytotoxicity (club cells) 736: Increase, Adenomas/carcinomas (bronchioloalveolar)
110 Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) Charles Wood BY-SA 424: Inhibition, Na+/I- symporter (NIS) 741: Increase, Adenomas/carcinomas (follicular cell)
111 Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) Charles Wood BY-SA 1614: Decrease, androgen receptor activation 745: Increase, Leydig cell tumors
112 Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) Charles Wood BY-SA 746: Increase, Dopaminergic activity 773: Increase, Endometrial adenocarcinomas
171 Chronic cytotoxicity of the serous membrane leading to pleural/peritoneal mesotheliomas in the rat. Charles Wood BY-SA None 1090: Increased, mesotheliomas
170 Anti-dopaminergic activity leading to mammary adenomas and carcinomas in the SD rat Charles Wood BY-SA None 1079: Increased, Adenomas/carcinomas (mammary)
169 GnRH pulse disruption leading to pituitary adenomas and carcinomas in the SD rat. Charles Wood BY-SA None 1082: Increased, adenomas (pituitary)
168 GnRH pulse disruption leading to mammary adenomas and carcinomas in the SD rat. Charles Wood BY-SA None 1079: Increased, Adenomas/carcinomas (mammary)
166 PPARalpha activation leading to pancreatic acinar tumors in the rat and mouse Charles Wood BY-SA None 1063: Increased, Pancreatic acinar tumors
165 Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse Charles Wood BY-SA None